Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: Issues and current strategies

Drugs

Volumn 73, Issue 14, 2013, Pages 1549-1568

  De Jesus Mari, Jair ^a,b   Tófoli, Luís Fernando ^c   Noto, Cristiano ^a   Li, Li M ^c   Diehl, Alessandra ^a   Claudino, Angélica M ^a   Juruena, Mario F ^b,d  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ALCOHOLISM; ANOREXIA NERVOSA; ANXIETY DISORDER; BIPOLAR DISORDER; BULIMIA; COGNITIVE THERAPY; COMORBIDITY; COST OF ILLNESS; DEPRESSION; DISTRESS SYNDROME; DRUG DEPENDENCE; DRUG INDICATION; EPILEPSY; EVIDENCE BASED PRACTICE; FACILITATION; FAMILY SERVICE; FUNCTIONAL STATUS; HEALTH BEHAVIOR; HIGH RISK POPULATION; HUMAN; MEDICATION COMPLIANCE; MENTAL DISEASE; NEUROLOGIC DISEASE; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; TREATMENT RESPONSE; WEIGHT GAIN;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; POVERTY; SUBSTANCE-RELATED DISORDERS;

EID: 84899647242     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0113-4     Document Type: Review

References (202)

1. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011;475(7354):27-30
2. World Health Organization. The global burden of disease: 2004 update. 2008. http://www. who. int/healthinfo/global-burden-disease/ 2004-report-update/en/
3. Hyman S, Chisholm D, Kessler R, et al. Mental disorders. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. Washington (DC): World Bank; 2006. p. 605-25
4. Gore FM, Bloem PJ, Patton GC, et al. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet. 2011;377(9783):2093-102
5. Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet. 2007;370(9590):859-77
6. Kohn R, Saxena S, Levav I, et al. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858-66
7. Patel V, Farooq S, Thara R. What is the best approach to treating schizophrenia in developing countries? PLoS Med. 2007;4(6): e159
8. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291(21):2581-90
9. World Health Organization. Improving access and use of psychotropic medicines. Mental health policy and service guidance package. 2005. http://www. who. int/mental-health/ policy/services/essentialpackage1v10/en/index. html
10. Sharan P, Levav I, Olifson S, et al. Research capacity for mental health in low-and middle-income countries: Results of a mapping project. Geneva, World Health Organization & Global Forum for Health Research. 2007. http://www. who. int/mental- health/MHRC-FullText. pdf
11. Patel V, Thornicroft G. Packages of care for mental, neurological, and substance use disorders in low-and middle-income countries: PLoS Medicine Series. PLoS Med. 2009;6(10):e1000160
12. World Health Organization. mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings: mental health Gap Action Programme (mhGAP). 2010. http://www. who. int/mental-health/evidence/ mhGAP-intervention-guide/en/
13. Dua T, Barbui C, Clark N, et al. Evidence-based guidelines for mental, neurological, and substance use disorders in low-and middle-income countries: summary of WHO recommendations. PLoS Med. 2011;8(11):e1001122
14. Bass JK, Bornemann TH, Burkey M, et al. A United Nations General Assembly Special Session for mental, neurological, and substance use disorders: the time has come. PLoS Med. 2012;9(1):e1001159
15. World Health Organization. WHO Model List of Essential Medicines. 2011. http://www. who. int/medicines/publications/ essentialmedicines/en/
16. World Health Organization. World Health Organization Assessment Instrument for Mental health Systems (WHO-AIMS) 2005. http://www. who. int/mental-health/evidence/AIMS-WHO-2-2. pdf
17. Araya R, Rojas G, Fritsch R, et al. Treating depression in primary care in low-income women in Santiago, Chile: a randomised controlled trial. Lancet. 2003;361(9362):995-1000
18. Lara MA, Navarro C, Rubi NA, et al. Outcome results of two levels of intervention in low-income women with depressive symptoms. Am J Orthopsychiatry. 2003;73(1):35-43
19. Fulton BD, Scheffler RM, Sparkes SP, et al. Health workforce skill mix and task shifting in low income countries: a review of recent evidence. Hum Resour Health. 2011;9(1):1
20. Lund C, Tomlinson M, De Silva M, et al. PRIME: a programme to reduce the treatment gap for mental disorders in five low-and middle-income countries. PLoS Med. 2012;9(12):e1001359
21. World Health Organization. Mental Health Gap Action Programme (mhGAP): scaling up care for mental, neurological and substance abuse disorders. 2008. http://www. who. int/mental- health/evidence/mhGAP/en/
22. Araya R, Flynn T, Rojas G, et al. Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. Am J Psychiatry. 2006;163(8): 1379-87
23. Patel V, Weiss HA, Chowdhary N, et al. Lay health worker led intervention for depressive and anxiety disorders in India: impact on clinical and disability outcomes over 12 months. Br J Psychiatry. 2011;199(6):459-66
24. Patel V, Weiss HA, Chowdhary N, et al. Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial. Lancet. 2010;376(9758):2086-95
25. Ormel J, VonKorff M, Ustun TB, et al. Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA. 1994;272(22):1741-8
26. Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry. 2000;61(Suppl 5):4-12 discussion 3-4
27. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162-71
28. Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry. 2007;6(3):168-76
29. Gater R, Tansella M, Korten A, et al. Sex differences in the prevalence and detection of depressive and anxiety disorders in general health care settings: report from the World Health Organization Collaborative Study on Psychological Problems in General Health Care. Arch Gen Psychiatry. 1998;55(5):405-13
30. Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. Am Fam Physician. 2009; 80(3):239-45
31. Markarian Y, Larson MJ, Aldea MA, et al. Multiple pathways to functional impairment in obsessive-compulsive disorder. Clin Psychol Rev. 2010;30(1):78-88
32. Toole MJ, Waldman RJ. The public health aspects of complex emergencies and refugee situations. Annu Rev Public Health. 1997;18:283-312
33. Roberts B, Browne J. A systematic review of factors influencing the psychological health of conflict-affected populations in lowand middle-income countries. Glob Public Health. 2011; 6(8):814-29
34. Keyes CL, Ryff CD. Somatization and mental health: a comparative study of the idiom of distress hypothesis. Soc Sci Med. 2003;57(10):1833-45
35. Escobar JI, Gureje O. Influence of cultural and social factors on the epidemiology of idiopathic somatic complaints and syndromes. Psychosom Med. 2007;69(9):841-5
36. Tofoli LF, Andrade LH, Fortes S. Somatization in Latin America: a review of the classification of somatoform disorders, functional syndromes and medically unexplained symptoms. Rev Bras Psiquiatr. 2011;33(Suppl 1):S59-80
37. Kroenke K. Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions. J Psychosom Res. 2006;60(4):335-9
38. Fink P, Toft T, Hansen MS, et al. Symptoms and syndromes of bodily distress: an exploratory study of 978 internal medical, neurological, and primary care patients. Psychosom Med. 2007;69(1):30-9
39. Fink P, Schroder A. One single diagnosis, bodily distress syndrome, succeeded to capture 10 diagnostic categories of functional somatic syndromes and somatoform disorders. J Psychosom Res. 2010;68(5):415-26
40. Creed F, Henningsen P, Fink P. Medically unexplained symptoms, somatisation, and bodily distress: developing better clinical services. Cambridge: Cambridge University Press; 2011
41. Sartorius N, Ustun TB, Lecrubier Y, et al. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry Suppl. 1996;30:38-43
42. Weich S, McBride O, Hussey D, et al. Latent class analysis of co-morbidity in the Adult Psychiatric Morbidity Survey in England 2007: implications for DSM-5 and ICD-11. Psychol Med. 2011;41(10):2201-12
43. Hanel G, Henningsen P, Herzog W, et al. Depression, anxiety, and somatoform disorders: vague or distinct categories in primary care? Results from a large cross-sectional study. J Psychosom Res. 2009;67(3):189-97
44. Gros DF, Magruder KM, Ruggiero KJ, et al. Comparing the symptoms of posttraumatic stress disorder with the distress and fear disorders. J Nerv Ment Dis. 2012;200(11):967-72
45. World Health Organization. Project atlas: resources for mental health and neurological disorders. 2005. http://apps. who. int/ globalatlas/default. asp
46. World Health Organization. Mental health atlas 2011. 2011. http://www. who. int/mental-health/publications/mental-health-atlas-2011/en/
47. Bruckner TA, Scheffler RM, Shen G, et al. The mental health workforce gap in low-and middle-income countries: a needsbased approach. Bull World Health Organ. 2011;89(3):184-94
48. Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci. 2011;13(4):423-37
49. National Institute for Clinical Excellence (NICE). Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. London: National Institute for Clinical Excellence (Great Britain); 2011
50. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008;8(2):235-57
51. Stein MB, Goin MK, Pollack MH, et al. Practice guideline for the treatment of patients with panic disorder. 2nd ed. Arlington: American Psychiatric Publishing; 2010
52. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. 2010;71(7):839-54
53. Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342:d1199
54. Lader M. Benzodiazepines revisited-will we ever learn? Addiction. 2011;106(12):2086-109
55. National Institute for Clinical Excellence (NICE). Obsessivecompulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. London: National Institute for Clinical Excellence (Great Britain); 2005
56. Koran LM, Hanna GL, Hollander E, et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7 Suppl):5-53
57. Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;(4):CD005473
58. Blanco C, Raza MS, Schneier FR, et al. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol. 2003;6(4):427-42
59. Choy Y, Fyer AJ, Lipsitz JD. Treatment of specific phobia in adults. Clin Psychol Rev. 2007;27(3):266-86
60. Black DW. Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders. CNS Spectr. 2006;11(10 Suppl 12):29-33
61. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003;(1):CD003383
62. Miyasaka LS, Atallah AN, Soares BG. Valerian for anxiety disorders. Cochrane Database Syst Rev. 2006;(4):CD004515
63. Miyasaka LS, Atallah AN, Soares BG. Passiflora for anxiety disorder. Cochrane Database Syst Rev. 2007;(1):CD004518
64. Faustino TT, Almeida RB, Andreatini R. Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies. Rev Bras Psiquiatr. 2010;32(4):429-36
65. Roberts NP, Kitchiner NJ, Kenardy J, et al. Early psychological interventions to treat acute traumatic stress symptoms. Cochrane Database Syst Rev. 2010;(3):CD007944
66. Agorastos A, Marmar CR, Otte C. Immediate and early behavioral interventions for the prevention of acute and posttraumatic stress disorder. Curr Opin Psychiatry. 2011;24(6):526-32
67. Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry. 2004;161(11 Suppl):3-31
68. National Collaborating Centre for Mental Health (Great Britain), National Institute for Clinical Excellence (Great Britain). Posttraumatic stress disorder: the management of PTSD in adults and children in primary and secondary care. National clinical practice guideline. 2005(no 26):vii
69. Jackson JL, O'Malley PG, Kroenke K. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectr. 2006;11(3):212-22
70. Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med. 2007;69(9):881-8
71. Lowe B, Spitzer RL, Williams JB, et al. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. Gen Hosp Psychiatry. 2008;30(3):191-9
72. Fink P, Rosendal M. Recent developments in the understanding and management of functional somatic symptoms in primary care. Curr Opin Psychiatry. 2008;21(2):182-8
73. Smith GR. The epidemiology and treatment of depression when it coexists with somatoform disorders, somatization, or pain. Gen Hosp Psychiatry. 1992;14(4):265-72
74. Janca A, Isaac M, Ventouras J. Towards better understanding and management of somatoform disorders. Int Rev Psychiatry. 2006;18(1):5-12
75. Arnold LM. Management of psychiatric comorbidity in fibromyalgia. Curr Psychiatry Rep. 2006;8(3):241-5
76. Arnold LM. Management of fibromyalgia and comorbid psychiatric disorders. J Clin Psychiatry. 2008;69(Suppl 2):14-9
77. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81(12): 1372-3
78. National Institute for Clinical Excellence (NICE). Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management of CFS/ME in adults and children. London: National Institute for Clinical Excellence; 2007
79. National Institute for Clinical Excellence (NICE). Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care. London: National Institute for Clinical Excellence; 2008
80. Avellaneda Fernandez A, Perez Martin A, Izquierdo Martinez M, et al. Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry. 2009;9(Suppl 1):S1
81. Kreijkamp-Kaspers S, Brenu EW, Marshall S, et al. Treating chronic fatigue syndrome-a study into the scientific evidence for pharmacological treatments. Aust Fam Physician. 2011;40(11):907-12
82. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11): e442
83. Lopez D, Mathers D, Ezzati M, et al. Global burden of disease and risk factors. New York: Oxford University Press and The World Bank; 2006
84. Sarna A, Pujari S, Sengar AK, et al. Adherence to antiretroviral therapy & its determinants amongst HIV patients in India. Indian J Med Res. 2008;127(1):28-36
85. Ronalds C, Creed F, Stone K, et al. Outcome of anxiety and depressive disorders in primary care. Br J Psychiatry. 1997; 171:427-33
86. Busnello ED, Tannous L, Gigante L, et al. Diagnostic reliability in mental disorders of the International Classification of Diseases in primary care. Rev Saude Publica. 1999;33(5):487-94
87. MariJde J, Iacoponi E, Williams P, et al. Detection of psychiatric morbidity in the primary medical care setting in Brazil. Rev Saude Publica. 1987;21(6):501-7
88. Juruena MF, Calil HM, Fleck MP, et al. Melancholia in Latin American studies: a distinct mood disorder for the ICD-11. Rev Bras Psiquiatr. 2011;33(Suppl 1):S37-58
89. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-58
90. National Collaborating Centre for Mental Health (Great Britain), National Institute for Health and Clinical Excellence (Great Britain), Royal College of Psychiatrists., et al. Depression: the treatment and management of depression in adults. Updated ed. London: British Psychological Society and the Royal College of Psychiatrists; 2010
91. Hetrick S, Merry S, McKenzie J, et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2007;(3): CD004851
92. Patel V, Chisholm D, Rabe-Hesketh S, et al. Efficacy and costeffectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: a randomised, controlled trial. Lancet. 2003;361(9351):33-9
93. Rojas G, Fritsch R, Solis J, et al. Treatment of postnatal depression in low-income mothers in primary-care clinics in Santiago, Chile: a randomised controlled trial. Lancet. 2007;370(9599):1629-37
94. Kaymaz N, van Os J, Loonen AJ, et al. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2008;69(9):1423-36
95. Fleck MP, Berlim MT, Lafer B, et al. Review of the guidelines of the Brazilian Medical Association for the treatment of depression (Complete version). Rev Bras Psiquiatr. 2009; 31(Suppl 1):S7-17
96. Fleck MP, Lafer B, Sougey EB, et al. Guidelines of the Brazilian Medical Association for the treatment of depression (complete version). Rev Bras Psiquiatr. 2003;25(2):114-22
97. Barbui C, Cipriani A, Patel V, et al. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry. 2011;198(1):11-6 sup 1
98. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45
99. World Health Organization. The World Health Report 2002: reducing risks, promoting healthy life. 2002. http://www. who. int/whr/2002/en/
100. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543-52
101. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241-51
102. Strakowski SM, DelBello MP. The co-occurrence of bipolar and substance use disorders. Clin Psychol Rev. 2000;20(2): 191-206
103. Batista TA, Baes CVW, Juruena MF. Efficacy of psychoeducation in bipolar patients: systematic review of randomized trials. Psychol Neurosci. 2011;4(3):409-16
104. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3): 225-55
105. de Jesus MJ, Razzouk D, Thara R, et al. Packages of care for schizophrenia in low-and middle-income countries. PLoS Med. 2009;6(10):e1000165
106. Lora A, Kohn R, Levav I, et al. Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low-and middle-income countries. Bull World Health Organ. 2012;90(1):47-54 A-B
107. Bushe CJ, Taylor M, Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol. 2010;24(4 Suppl):17-25
108. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141
109. Walley J, Lawn JE, Tinker A, et al. Primary health care: making Alma-Ata a reality. Lancet. 2008;372(9642):1001-7
110. Xiong W, Phillips MR, Hu X, et al. Family-based intervention for schizophrenic patients in China. A randomised controlled trial. Br J Psychiatry. 1994;165(2):239-47
111. Healey A, Knapp M, Astin J, et al. Cost-effectiveness evaluation of compliance therapy for people with psychosis. Br J Psychiatry. 1998;172:420-4
112. Saxena S, Thornicroft G, Knapp M, et al. Resources for mental health: scarcity, inequity, and inefficiency. Lancet. 2007; 370(9590):878-89
113. Chisholm D, Gureje O, Saldivia S, et al. Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bull World Health Organ. 2008; 86(7):542-51
114. Brietzke E, Araripe Neto AG, Dias A, et al. Early intervention in psychosis: a map of clinical and research initiatives in Latin America. Rev Bras Psiquiatr. 2011;33(Suppl 2):s213-24
115. Rosenbloom M. Chlorpromazine and the psychopharmacologic revolution. JAMA. 2002;287(14):1860-1
116. Kane JM. An evidence-based strategy for remission in schizophrenia. J Clin Psychiatry. 2008;69(Suppl 3):25-30
117. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-20
118. American Psychiatry Association (APA). Practice guideline for the treatment of patients with schizophrenia, 2nd edn. Washington (DC): American Psychiatric Press; 2004
119. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6(3): 132-91
120. Royal Australian, New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia, Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005;39(1-2):1-30
121. Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2006;(4): CD003082
122. Thornley B, Rathbone J, Adams CE, et al. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2003;(2):CD000284
123. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-97
124. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23
125. Huskamp HA. Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value. Health Aff (Millwood). 2006;25(3):635-46
126. Stahl SM, Grady MM. Stahl's essential psychopharmacology: the prescriber's guide. 4th ed. Cambridge: Cambridge University Press; 2011
127. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull. 1998;24(1):11-20 discussion 32
128. Leucht S, Heres S, Kissling W, et al. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol. 2011;14(2):269-84
129. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93
130. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapineinduced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162-7
131. Velligan DI, Diamond PM, Mintz J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull. 2008;34(3):483-93
132. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23(4):637-51
133. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3): 241-7
134. David A, Adams CE, Eisenbruch M, et al. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev. 2005;(1):CD000307
135. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92
136. National Collaborating Centre for Mental Health (NCCMH), National Institute for Clinical Excellence (Great Britain). Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Updated edition. Leicester and London: The British Psychological Society and the Royal College of Psychiatrists; 2010
137. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65(7):932-9
138. Swanson SA, Crow SJ, Le Grange D, et al. Prevalence and correlates of eating disorders in adolescents. Results from the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry. 2011;68(7):714-23
139. Smink FR, van Hoeken D, Hoek HW. Epidemiology of eating disorders: incidence, prevalence and mortality rates. Curr Psychiatry Rep. 2012;14(4):406-14
140. Hay P. The epidemiology of eating disorder behaviors: an Australian community-based survey. Int J Eat Disord. 1998;23(4):371-82
141. Hudson JI, Hiripi E, Pope HG Jr, et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348-58
142. Grucza RA, Przybeck TR, Cloninger CR. Prevalence and correlates of binge eating disorder in a community sample. Compr Psychiatry. 2007;48(2):124-31
143. Striegel-Moore RH, Dohm FA, Kraemer HC, et al. Eating disorders in white and black women. Am J Psychiatry. 2003;160(7):1326-31
144. Hay PJ, Mond J, Buttner P, et al. Eating disorder behaviors are increasing: findings from two sequential community surveys in South Australia. PLoS One. 2008;3(2):e1541
145. Chen H, Jackson T. Prevalence and sociodemographic correlates of eating disorder endorsements among adolescents and young adults from China. Eur Eat Disord Rev. 2008;16(5):375-85
146. de Souza Ferreira JE, da Veiga GV. Eating disorder risk behavior in Brazilian adolescents from low socio-economic level. Appetite. 2008;51(2):249-55
147. Chandra PS, Abbas S, Palmer R. Are eating disorders a significant clinical issue in urban India? A survey among psychiatrists in Bangalore. Int J Eat Disord. 2012;45(3):443-6
148. Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155-62
149. American Psychiatric Association. Diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000
150. Keel PK, Brown TA, Holland LA, et al. Empirical classification of eating disorders. Annu Rev Clin Psychol. 2012;8:381-404
151. Striegel-Moore RH, Bulik CM. Risk factors for eating disorders. Am Psychol. 2007;62(3):181-98
152. Khandelwal SK, Sharan P, Saxena S. Eating disorders: an Indian perspective. Int J Soc Psychiatry. 1995;41(2):132-46
153. Lee S, Lee AM, Ngai E, et al. Rationales for food refusal in Chinese patients with anorexia nervosa. Int J Eat Disord. 2001;29(2):224-9
154. Viernes N, Zaidan ZA, Dorvlo AS, et al. Tendency toward deliberate food restriction, fear of fatness and somatic attribution in cross-cultural samples. Eat Behav. 2007;8(3):407-17
155. Treasure J, Claudino AM, Zucker N. Eating disorders. Lancet. 2010;375(9714):583-93
156. Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41(10):2177-82
157. Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev. 2003;(4):CD003391
158. Hay PJ, Claudino AM. Bulimia nervosa. Clin Evid (Online). 2010;07:1009
159. Reas DL, Grilo CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring). 2008;16(9):2024-38
160. Stefano SC, Bacaltchuk J, Blay SL, et al. Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis. Eat Behav. 2008;9(2):129-36
161. Hay PJ, Claudino AM. Clinical psychopharmacology of eating disorders: a research update. Int J Neuropsychopharmacol. 2012; 15(2):209-22
162. Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 1988;49(7):262-6
163. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch Gen Psychiatry. 1992;49(2):139-47
164. Romano SJ, Halmi KA, Sarkar NP, et al. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry. 2002;159(1):96-102
165. Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57(3):301-9
166. McElroy SL, Casuto LS, Nelson EB, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry. 2000;157(6):1004-6
167. Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord. 2005;38(4):295-300
168. McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039-48
169. Claudino AM, de Oliveira IR, Appolinario JC, et al. Doubleblind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68(9):1324-32
170. Hay PP, Bacaltchuk J, Stefano S, et al. Psychological treatments for bulimia nervosa and binging. Cochrane Database Syst Rev. 2009;(4):CD000562
171. United Nations Office on Drug and Crime (UNODC). Vienna World Drug Report; 2011
172. Buckingham E, Schrage E, Cournos F. Why the treatment of mental disorders is an important component of HIV prevention among people who inject drugs. Adv Prev Med. 2013;2013: 690386
173. Miller WR, Forcehimes A, Zweben A. Treating addiction: a guide for professionals. New York: Guilford Press; 2011
174. May PA, Brooke L, Gossage JP, et al. Epidemiology of fetal alcohol syndrome in a South African community in the Western Cape Province. Am J Public Health. 2000;90(12):1905-12
175. Jupp B, Lawrence AJ. New horizons for therapeutics in drug and alcohol abuse. Pharmacol Ther. 2010;125(1):138-68
176. Shorter D, Kosten TR. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med. 2011;9:119
177. Addolorato G, Leggio L, Hopf FW, et al. Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology. 2012;37(1):163-77
178. Segatto ML, Andreoni S, de Souza e Silva R. Brief motivational interview and educational brochure in emergency room settings for adolescents and young adults with alcohol-related problems: a randomized single-blind clinical trial. Rev Bras Psiquiatr. 2011;33(3):225-33
179. Saitz R, O'Malley SS. Pharmacotherapies for alcohol abuse: withdrawal and treatment. Med Clin N Am. 1997;81(4):881-907
180. Raupach T, van Schayck CP. Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs. 2011;25(5):371-82
181. Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs. 2010;70(18):2357-72
182. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol. 2003;16(2):165-70
183. Burneo JG, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy Res. 2005;66(1-3):63-74
184. Fernandes PT, Salgado PC, Noronha AL, et al. Epilepsy stigma perception in an urban area of a limited-resource country. Epilepsy Behav. 2007;11(1):25-32
185. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12(4):540-6
186. Leonardi M, Ustun TB. The global burden of epilepsy. Epilepsia. 2002;43(Suppl 6):21-5
187. Institute of Medicine (U. S. ). Committee on the Public Health Dimensions of the Epilepsies, England MJ. Epilepsy across the spectrum: promoting health and understanding. Washington, DC: National Academies Press; 2012
188. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989; 30(4):389-99
189. Smith DB, Mattson RH, Cramer JA, et al. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia. 1987;28(Suppl 3):S50-8
190. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10(5):446-56
191. Sirven JI, Sperling M, Wingerchuk DM. Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database Syst Rev. 2001;(3):CD001902
192. Insel TR, Wang PS. Rethinking mental illness. JAMA. 2010; 303(19):1970-1
193. Heuzenroeder L, Donnelly M, Haby MM, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry. 2004;38(8):602-12
194. Laxminarayan R, Mills AJ, Breman JG, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet. 2006;367(9517):1193-208
195. Pike KM, Borovoy A. The rise of eating disorders in Japan: issues of culture and limitations of the model of ''westernization''. Cult Med Psychiatry. 2004;28(4):493-531
196. Becker AE. Television, disordered eating, and young women in Fiji: negotiating body image and identity during rapid social change. Cult Med Psychiatry. 2004;28(4):533-59
197. Kayano M, Yoshiuchi K, Al-Adawi S, et al. Eating attitudes and body dissatisfaction in adolescents: cross-cultural study. Psychiatry Clin Neurosci. 2008;62(1):17-25
198. Raw M, McNeill A, Murray R. Case studies of tobacco dependence treatment in Brazil, England, India, South Africa and Uruguay. Addiction. 2010;105(10):1721-8
199. Benegal V, Chand PK, Obot IS. Packages of care for alcohol use disorders in low-and middle-income countries. PLoS Med. 2009;6(10):e1000170
200. Kimberly JR, McLellan AT. The business of addiction treatment: a research agenda. J Subst Abuse Treat. 2006;31(3): 213-9
201. Sorsdahl KR, Stein DJ. Knowledge of and stigma associated with mental disorders in a South african community sample. J Nerv Ment Dis. 2010;198(10):742-7
202. Meyer AC, Dua T, Ma J, et al. Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ. 2010;88(4):260-6.